A Beginner''s Guide to Targeted Cancer Treatments and Cancer Immunotherapy
English
By (author): Elaine Vickers
Demystifying the science behind new cancer treatments
A clear and accessible guide written in everyday language for nurses and other healthcare professionals
A Beginners Guide to Targeted Cancer Treatments and Cancer Immunotherapy helps readers understand the science behind many of the newer drug treatments for cancer. Assuming only a basic familiarity with cell biology, this easy-to-digest guide describes how our increased understanding of cancer has been translated into the creation of new cancer treatments with a wide range of targets.
Gifted communicator and educator Dr. Elaine Vickers helps you understand the mechanisms of a wide range of individual targeted therapies and immunotherapies enabling you to communicate effectively with your colleagues and patients. Concise chapters explain how new cancer drugs and immunotherapies work, discuss their benefits, identify their limitations, and more.
Now in its second edition, this popular handbook is fully revised to reflect the latest developments in targeted drug therapies and immunotherapies. Entirely new chapters on advancements in various immunotherapies are accompanied by more than 100 new and updated color illustrations.
- Provides an up-to-date overview of relevant treatment targets for all major cancer types, including hematological cancers
- Describes cancer biology and the relationship between cancer and the immune system
- Offers valuable insights into cell communication pathways as a common target
- Covers small molecule drugs, antibody-based treatments, and cellular therapies, including novel immunotherapies
A Beginners Guide to Targeted Cancer Treatments and Cancer Immunotherapy is a must-have resource for trainees, practicing nurses, and other healthcare professionals involved in the care of cancer patients, as well as non-specialists who encounter cancer data or cancer terminology in their field.
See moreWill deliver when available. Publication date 14 Nov 2024